AGAP2
Reactivity: Human
WB, ELISA, IF (cc), IF (p), IHC (p), IHC (fro)
Host: Rabbit
Polyclonal
unconjugated
Application Notes
Peptide ELISA: 1/8000. Western blot: 0.3 - 1 μg/mL. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
0,5 mg/mL
Buffer
Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
4 °C/-20 °C
Storage Comment
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
Target
AGAP2
(ArfGAP with GTPase Domain, Ankyrin Repeat and PH Domain 2 (AGAP2))
Phosphoinositide 3 kinase enhancer (PIKE) is a recently identified nuclear GTPase that interacts with nuclear phosphoinositide 3-kinase (PI3 kinase) to stimulate its lipid kinase activity. PIKE exists in multiple isoforms, a shorter C-terminal isoform (PIKE-A) has also been identified as centaurin gamma 1. The longest isoform (PIKE-L) has been shown to bind to the adaptor protein Homer and thereby link to metabotropic glutamate receptors, leading to activation of PI3 kinase activity and prevention of neuronal apoptosis. Overexpression of PIKE-A enhances Akt activity and promotes cancer cell invasion, whereas decreased expression of PIKE-A via dominant negative expression of PIKE-A or PIKE-A knockdown inhibits these processes. In many human cancers, expression of PIKE-A is enhanced, leading to increased Akt activity and preventing apoptosis.Synonyms: Arf-GAP GTPase ANK repeat and PH domain-containing protein 2, Centaurin-gamma-1, GGAP2, GTP-binding and GTPase-activating protein 2, KIAA0167, PIKE, Phosphatidylinositol-3-kinase enhancer